BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29693280)

  • 1. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
    Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
    Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment.
    Tabei T; Natsume I; Kobayashi K
    Int J Urol; 2017 Sep; 24(9):708-710. PubMed ID: 28734029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
    Dizman N; Bergerot P; Bergerot C; Lanman RB; Raymond VM; Banks KC; Jones J; Pal SK
    Eur Urol; 2018 Feb; 73(2):308-310. PubMed ID: 28844598
    [No Abstract]   [Full Text] [Related]  

  • 4. [A CASE OF RENAL CELL CARCINOMA THAT ONCE NIVOLUMAB HAD BEEN EFFECTIVE IN METASTATIC LESION AND MADE PRIMARY TUMOR RESECTABLE].
    Tsukahara S; Nagatomi Y; Otsubo S; Hasegawa S
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):32-35. PubMed ID: 31956216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
    Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
    J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma.
    Akbaraly T; Saguintaah M; Topart D; Sirvent N
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):251-252. PubMed ID: 29420369
    [No Abstract]   [Full Text] [Related]  

  • 7. [A Case of Rheumatoid Arthritis Developed during Treatment with Nivolumab for Renal Cell Carcinoma].
    Tomizawa M; Nakai Y; Maesaka F; Owari T; Hara R; Miyake M; Inoue T; Anai S; Tanaka N; Fujimoto K
    Hinyokika Kiyo; 2018 Oct; 64(10):397-401. PubMed ID: 30543737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].
    Hattahara K; Yamasaki T; Sawada A; Tanigaki K; Endo S; Teramoto Y; Banno H; Fuchigami Y; Suzuki R; Fujiwara M; Hida T; Yoshino T; Kita Y; Goto T; Akamatsu S; Saito R; Kobayashi T; Inoue T; Ogawa O
    Hinyokika Kiyo; 2019 May; 65(5):157-161. PubMed ID: 31247693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete Response of a Patient With Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint Inhibitor.
    El Mouallem N; Smith SC; Paul AK
    J Oncol Pract; 2018 Aug; 14(8):511-513. PubMed ID: 29920137
    [No Abstract]   [Full Text] [Related]  

  • 10. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newly developing brain metastases during nivolumab therapy for metastatic renal cell carcinoma: A case series in two Japanese institutions.
    Ishihara H; Kondo T; Takagi T; Yoshida K; Okumi M; Tanabe K
    Int J Urol; 2019 Aug; 26(8):849-850. PubMed ID: 31115103
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
    Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
    Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
    Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
    Eur Urol; 2017 Dec; 72(6):962-971. PubMed ID: 28262413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NICE Guidance - Nivolumab for previously treated advanced renal cell carcinoma: © NICE (2017) Nivolumab for previously treated advanced renal cell carcinoma.
    BJU Int; 2018 Sep; 122(3):362-370. PubMed ID: 30187657
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Int J Clin Oncol; 2020 Apr; 25(4):705-712. PubMed ID: 31858306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
    Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
    Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
    [No Abstract]   [Full Text] [Related]  

  • 19. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
    Rexer H; Steiner T; Grünwald V
    Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.
    Mollica V; Rizzo A; Tassinari E; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Anticancer Drugs; 2021 Jan; 32(1):74-81. PubMed ID: 33290315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.